These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21964594)

  • 1. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.
    Henstridge CM; Balenga NA; Kargl J; Andradas C; Brown AJ; Irving A; Sanchez C; Waldhoer M
    Mol Endocrinol; 2011 Nov; 25(11):1835-48. PubMed ID: 21964594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
    Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
    J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.
    Kargl J; Balenga N; Parzmair GP; Brown AJ; Heinemann A; Waldhoer M
    J Biol Chem; 2012 Dec; 287(53):44234-48. PubMed ID: 23161546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
    Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic synthesis of novel phosphoglycolipid analogues as potential agonists of GPR55.
    Abe J; Guy AT; Ding F; Greimel P; Hirabayashi Y; Kamiguchi H; Ito Y
    Org Biomol Chem; 2020 Nov; 18(41):8467-8473. PubMed ID: 33063071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.
    Liu B; Song S; Ruz-Maldonado I; Pingitore A; Huang GC; Baker D; Jones PM; Persaud SJ
    Diabetes Obes Metab; 2016 Dec; 18(12):1263-1273. PubMed ID: 27561953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
    Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning.
    Mosca MG; Mangini M; Cioffi S; Barba P; Mariggiò S
    Cell Commun Signal; 2021 Apr; 19(1):48. PubMed ID: 33902596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
    Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
    Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the lysophosphatidylinositol/GPR55 axis in cancer.
    Falasca M; Ferro R
    Adv Biol Regul; 2016 Jan; 60():88-93. PubMed ID: 26588872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
    Yang H; Zhou J; Lehmann C
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
    Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
    J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
    Anavi-Goffer S; Irving AJ; Ross RA
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the natural ligand of GPR55?
    Okuno T; Yokomizo T
    J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
    Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
    Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preference for Glucose over Inositol Headgroup during Lysolipid Activation of G Protein-Coupled Receptor 55.
    Guy AT; Kano K; Ohyama J; Kamiguchi H; Hirabayashi Y; Ito Y; Matsuo I; Greimel P
    ACS Chem Neurosci; 2019 Jan; 10(1):716-727. PubMed ID: 30346710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
    Piñeiro R; Maffucci T; Falasca M
    Oncogene; 2011 Jan; 30(2):142-52. PubMed ID: 20838378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.